OXYTROL FOR WOMEN

Oxybutynin 3.9mg/24h, Transdermal patch - Biweekly

Alcohol

· Severity: Major

· Notes for Consumers: Do not drink alcohol while taking this medication. Drinking alcohol while taking this medication can cause serious side effects, such as central nervous system (CNS) depression, and can increase the risk of falling. Call emergency services right away if you experience symptoms of CNS depression: slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, trouble staying awake.

· Notes for Professionals: Advise patients to avoid alcohol consumption while taking oxybutynin. Alcohol is a CNS-depressant and may cause additive sedative effects when used concomitantly with oxybutynin.

Oxybutynin 3.9mg/24h, Transdermal patch - Biweekly

Caffeine-containing Foods/Beverages

· Severity: Mild

· Notes for Consumers: The intake of beverages containing caffeine may decrease the actions of oxybutynin because caffeine may increase urination. You may wish to limit your caffeine intake (including intake of coffee, colas, teas, or herbal supplements) while taking oxybutynin.

· Notes for Professionals: Consuming greater than 400 mg/day caffeine has been associated with the development of urinary incontinence. Caffeine may aggravate bladder symptoms and counteract the effectiveness of drugs used to treat overactive bladder such as oxybutynin.

Oxybutynin 3.9mg/24h, Transdermal patch - Biweekly

Grapefruit juice

· Severity: Moderate

· Notes for Consumers: Grapefruit juice and grapefruit-containing foods may increase the side effects of oxybutynin. Do not significantly increase grapefruit juice intake while taking this drug, or avoid grapefruit juice if possible. Discuss any new or worsening side effects, such as confusion, constipation, dizziness, difficulty with urination, drowsiness, dry mouth and eyes, changes in vision, palpitations, or fast heartbeat with your health care provider. Do not drive or operate machinery until you know how these drugs affect you.

· Notes for Professionals: Oxybutynin is metabolized by CYP3A4. Inhibitors of the CYP3A4 enzyme system, such as grapefruit juice, may alter oxybutynin mean pharmacokinetic parameters. The clinical significance of such interactions is not known; however, the manufacturer recommends that caution be used when oxybutynin is co-administered with CYP3A4 inhibitors.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>